Bioventus Inc - Class A

Research Bioventus Inc - Class A (BVS) on Bullrun: valuation model: 8.7% overvalued, market cap USD 662.58M, P/E 23.7. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerBVS
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryMedical Devices
• CurrencyUSD
• Valuation signal8.7% overvalued
• Market capUSD 662.58M
• P/E23.7
• Financial periodFY2025
• RevenueUSD 568.09M
• Revenue growth-0.9%
• Net incomeUSD 22.73M
• Free cash flowUSD 72.11M
• Gross margin68.3%

Valuation Snapshot

Bullrun's latest valuation model marks Bioventus Inc - Class A as 8.7% overvalued; latest market cap is USD 662.58M; P/E is 23.7.

About Bioventus Inc - Class A

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis;

Frequently asked questions

Is Bioventus Inc - Class A overvalued or undervalued?

Bullrun's valuation model currently marks Bioventus Inc - Class A as 8.7% overvalued.

What is Bioventus Inc - Class A's market cap?

Bioventus Inc - Class A's market capitalization is USD 662.58M.

What is Bioventus Inc - Class A's P/E ratio?

Bioventus Inc - Class A's price-to-earnings (P/E) ratio is 23.7.

What does Bioventus Inc - Class A do?

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections;